Integrilin

Eptifibatide, the active ingredient in Integrilin, is a glycoprotein IIb/IIIa inhibitor presented as an injection solution for intravenous use. It provides antiplatelet therapy for adults with unstable angina, non‑ST elevation myocardial infarction (NSTEMI) and during percutaneous coronary intervention (PCI) to reduce thrombotic complications.

GNH USA supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required and regulatory support.

Integrilin (eptifibatide) is used as an antiplatelet agent in acute coronary syndromes and interventional cardiology.

- Unstable angina: reduces the risk of progression to myocardial infarction by inhibiting platelet aggregation during the acute phase. - Non‑ST elevation myocardial infarction (NSTEMI): facilitates early reperfusion and limits thrombus growth when combined with standard therapy. - Percutaneous coronary intervention (PCI): prevents intra‑procedural and post‑procedural platelet clumping, decreasing the incidence of ischemic complications.

Eptifibatide may be associated with several adverse reactions, ranging from frequent, mild events to rare but serious complications.

Common Side Effects: - Bleeding at catheter insertion sites: mild oozing that usually stops with pressure. - Minor bruising or hematoma: localized skin discoloration without significant blood loss. - Mild thrombocytopenia: slight drop in platelet count that resolves after therapy. - Nausea or vomiting: transient gastrointestinal discomfort. - Headache: mild to moderate intensity, often self‑limiting.

Serious or Rare Side Effects: - Severe or uncontrolled bleeding: may require transfusion or surgical intervention. - Acute profound thrombocytopenia: platelet count falls below 20,000/µL, increasing hemorrhage risk. - Allergic reactions including anaphylaxis: rash, swelling, respiratory distress necessitating emergency care. - Paradoxical myocardial infarction: rare clot formation despite antiplatelet therapy.

When using Integrilin, clinicians should observe several precautionary measures to minimize risks and ensure safe therapy.

- Bleeding risk: monitor patients for signs of hemorrhage, especially at invasive sites. - Thrombocytopenia: obtain baseline platelet count and repeat monitoring during treatment. - Renal impairment: adjust use or avoid in severe renal dysfunction due to altered clearance. - Concurrent anticoagulants: evaluate cumulative bleeding risk when combined with heparin or warfarin. - Hypersensitivity: discontinue immediately if an allergic reaction such as rash or anaphylaxis occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eptifibatide can interact with other agents that affect hemostasis or share metabolic pathways, requiring careful management.

Major Interactions (Avoid): - Heparin: concurrent use markedly increases the risk of major bleeding and may require dose reduction or alternative anticoagulation. - Other glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban): additive antiplatelet activity can lead to severe hemorrhage and should be avoided.

Moderate Interactions (Monitor Closely): - Warfarin: eptifibatide may enhance anticoagulant effect; monitor INR and adjust warfarin dose as needed. - Clopidogrel: combined antiplatelet therapy raises overall bleeding potential; observe for signs of occult bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair platelet function and increase gastrointestinal bleeding risk; use with caution.